Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Jerry Sadoff; Mathieu Le Gars; Georgi Shukarev; Dirk Heerwegh; Carla Truyers; Anne Marit de Groot; Jeroen Stoop; Sarah Tete; Wim Van Damme; Isabel Leroux-Roels; Pieter-Jan Berghmans; Murray Kimmel; Pierre Van Damme; Jan De Hoon; Williams Smith; Kathryn E. Stephenson; Dan H. Barouch; Stephen C. De Rosa; Kristen W. Cohen; M. Juliana McElrath; Emmanuel Cormier; Gert Scheper; Jenny Hendriks; Frank Struyf; Macaya Douoguih; Johan Van Hoof; Hanneke Schuitemaker

bioRxiv (2020) - Comments
doi: 10.1101/2020.09.23.20199604

Jerry Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit De Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath